BACKGROUND: Quantitative flow cytometry (QFCM) is being applied in the clinical flow cytometry laboratory for diagnosis, prognosis, and assessment of patients receiving antibody-based therapy. ABC values and the effect of technical variables on CD22 quantitation in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FCL), hairy cell leukemia (HCL) and normal B cells were studied. METHODS: The QuantiBrite System® was used to determine the level of CD22 expression (mean antibody bound per cell, ABC) by malignant and normal B cells. The intra-assay variability, number of cells required for precision, effect of delayed processing as well as shipment of peripheral blood specimens (delayed processing and exposure to noncontrolled environments), and the effect of paraformaldehyde fixation on assay results were studied. RESULTS: The QuantiBRITE method of measuring CD22 ABC is precise (median CV 1.6%, 95% confidence interval, 1.2-2.3%) but a threshold of 250 malignant cells is required for reliable CD22 ABC values. Delayed processing and overnight shipment of specimens resulted in significantly different ABC values whereas fixation for up to 12 h had no significant effect. ABC measurements determined that CD22 expression is lower than normal in ALL, CLL, FCL, and MCL but higher than normal in HCL. CONCLUSIONS: CD22 expression was atypical in the hematolymphoid malignancies studied and may have diagnostic utility. Technical variables such as cell number analyzed and delayed processing or overnight shipment of specimens impact significantly on the measurement of antigen expression by QFCM in the clinical laboratory. Published 2010 Wiley-Liss, Inc.
BACKGROUND: Quantitative flow cytometry (QFCM) is being applied in the clinical flow cytometry laboratory for diagnosis, prognosis, and assessment of patients receiving antibody-based therapy. ABC values and the effect of technical variables on CD22 quantitation in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FCL), hairy cell leukemia (HCL) and normal B cells were studied. METHODS: The QuantiBrite System® was used to determine the level of CD22 expression (mean antibody bound per cell, ABC) by malignant and normal B cells. The intra-assay variability, number of cells required for precision, effect of delayed processing as well as shipment of peripheral blood specimens (delayed processing and exposure to noncontrolled environments), and the effect of paraformaldehyde fixation on assay results were studied. RESULTS: The QuantiBRITE method of measuring CD22ABC is precise (median CV 1.6%, 95% confidence interval, 1.2-2.3%) but a threshold of 250 malignant cells is required for reliable CD22ABC values. Delayed processing and overnight shipment of specimens resulted in significantly different ABC values whereas fixation for up to 12 h had no significant effect. ABC measurements determined that CD22 expression is lower than normal in ALL, CLL, FCL, and MCL but higher than normal in HCL. CONCLUSIONS:CD22 expression was atypical in the hematolymphoid malignancies studied and may have diagnostic utility. Technical variables such as cell number analyzed and delayed processing or overnight shipment of specimens impact significantly on the measurement of antigen expression by QFCM in the clinical laboratory. Published 2010 Wiley-Liss, Inc.
Authors: Alan S Wayne; Robert J Kreitman; Harry W Findley; Glen Lew; Cynthia Delbrook; Seth M Steinberg; Maryalice Stetler-Stevenson; David J Fitzgerald; Ira Pastan Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Indu Arun; Jacqueline A Wulu; John E Janik; Gregory A Jasper; Constance M Yuan; David Venzon; Maryalice Stetler-Stevenson Journal: Cytometry B Clin Cytom Date: 2010-05 Impact factor: 3.058
Authors: Robert J Kreitman; Maryalice Stetler-Stevenson; Inger Margulies; Pierre Noel; David J P Fitzgerald; Wyndham H Wilson; Ira Pastan Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544
Authors: Prashant Tembhare; Constance M Yuan; John C Morris; John E Janik; Armando C Filie; Maryalice Stetler-Stevenson Journal: Am J Clin Pathol Date: 2012-02 Impact factor: 2.493
Authors: Nirali N Shah; Maryalice Stetler Stevenson; Constance M Yuan; Kelly Richards; Cindy Delbrook; Robert J Kreitman; Ira Pastan; Alan S Wayne Journal: Pediatr Blood Cancer Date: 2015-03-01 Impact factor: 3.167
Authors: Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron Journal: Cytometry B Clin Cytom Date: 2015-07-06 Impact factor: 3.058
Authors: Katherine R Calvo; Donald C Vinh; Irina Maric; Weixin Wang; Pierre Noel; Maryalice Stetler-Stevenson; Diane C Arthur; Mark Raffeld; Amalia Dutra; Evgenia Pak; Kyungjae Myung; Amy P Hsu; Dennis D Hickstein; Stefania Pittaluga; Steven M Holland Journal: Haematologica Date: 2011-04-20 Impact factor: 9.941
Authors: Elisabet E Manasanch; Dalia A Salem; Constance M Yuan; Nishant Tageja; Manisha Bhutani; Mary Kwok; Dickran Kazandjian; George Carter; Seth M Steinberg; Diamond Zuchlinski; Marcia Mulquin; Katherine Calvo; Irina Maric; Mark Roschewski; Neha Korde; Raul Braylan; Ola Landgren; Maryalice Stetler-Stevenson Journal: Leuk Lymphoma Date: 2014-10-30
Authors: Prashant R Tembhare; Constance M Yuan; David Venzon; Raul Braylan; Neha Korde; Elisabet Manasanch; Diamond Zuchlinsky; Katherine Calvo; Roger Kurlander; Manisha Bhutani; Nishant Tageja; Irina Maric; Marcia Mulquin; Mark Roschewski; Mary Kwok; David Liewehr; Ola Landgren; Maryalice Stetler-Stevenson Journal: Leuk Res Date: 2013-12-11 Impact factor: 3.156
Authors: Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner Journal: Clin Cancer Res Date: 2015-08-17 Impact factor: 12.531